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Abstract
Background  The aim of the study was 
to develop and validate measures of 
awareness of symptoms and risk factors for 
ovarian and cervical cancer (Ovarian and 
Cervical Cancer Awareness Measures).
Methods  Potentially relevant items were 
extracted from the literature and generated by 
experts. Four validation studies were carried 
out to establish reliability and validity. Women 
aged 21–67 years (n=146) and ovarian and 
cervical cancer experts (n=32) were included 
in the studies. Internal reliability was assessed 
psychometrically. Test-retest reliability was 
assessed over a 1-week interval. To establish 
construct validity, Cancer Awareness Measure 
(CAM) scores of cancer experts were compared 
with equally well-educated comparison groups. 
Sensitivity to change was tested by randomly 
assigning participants to read either a leaﬂ  et 
giving information about ovarian/cervical cancer 
or a leaﬂ  et with control information, and 
then completing the ovarian/cervical CAM.
Results  Internal reliability (Cronbach’s α=0.88 
for the ovarian CAM and α=0.84 for the cervical 
CAM) and test-retest reliability (r=0.84 and r=0.77 
for the ovarian and cervical CAMs, respectively) 
were both high. Validity was demonstrated 
with cancer experts achieving higher scores 
than controls [ovarian CAM: t(36)= –5.6, 
p<0.001; cervical CAM: t(38)= –3.7, p=0.001], 
and volunteers who were randomised to read 
a cancer leaﬂ  et scored higher than those who 
received a control leaﬂ  et [ovarian CAM: t(49)=7.5, 
p<0.001; cervical CAM: t(48)= –5.5, p<0.001].
Conclusions  This study demonstrates the 
psychometric properties of the ovarian and 
cervical CAMs and supports their utility 
in assessing ovarian and cervical cancer 
awareness in the general population.
Introduction
The UK Government’s support for rais-
ing public awareness of the early warning 
signs and risk factors of cancer is set out in 
the 2007 National Health Service (NHS) 
Cancer Reform Strategy (see http://tinyurl.
com/cancerreformstratergy) and has led to 
the creation of the National Awareness 
and Early Diagnosis Initiative (NAEDI). 
NAEDI aims to promote early diagnosis of 
cancer with a view to improving the UK’s 
relatively poor survival rates.1 It com-
prises four work-streams, one of which 
(research, evaluation and monitoring) has 
been instrumental in the development of a 
measure of cancer awareness.2 The Cancer 
Research UK Cancer Awareness Measure 
(CAM) was developed to provide a stand-
ardised and valid measure of public aware-
ness of cancer, either in whole populations 
or specific subgroups. It is hypothesised 
that low levels of cancer awareness in the 
UK population may be partly responsible 
for delayed presentation with symptoms, 
leading to later-stage diagnoses. The CAM 
was developed to enable researchers and 
campaigning groups to systematically assess 
this possibility and to measure the impact 
of their awareness-raising activities.
In addition to the generic CAM, there 
is a need for site-specific versions, particu-
larly for cancers where poor knowledge of 
risk factors and early warning signs may be 
associated with delayed presentation and 
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Key messgae points
▶   This study demonstrates the psychometric properties 
of the ovarian and cervical Cancer Awareness 
Measures (CAMs).
▶   The ovarian and cervical CAMs demonstrated good 
reliability and validity in a series of development 
studies.
▶   The ovarian and cervical CAMs can be used to assess 
population levels of awareness, monitor changes in 
awareness over time and evaluate awareness-raising 
interventions.
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thus have an impact on survival. The aim of the present 
research was to develop and validate two versions of the 
CAM that were specific to ovarian and cervical cancer.
Ovarian cancer is the fifth most common cancer in 
women in the UK with around 6800 new cases each 
year. Survival rates have increased since the 1970s, 
with the latest figures showing 5-year survival at 40%.3 
Thanks to a successful screening programme, cervical 
cancer is less common. Around 2800 new cases are 
diagnosed in the UK each year and 940 women die of 
the disease, but as with ovarian cancer, survival rates 
are considerably poorer than in other European coun-
tries.4 Thomson and Forman’s review of EUROCARE 
(European Cancer Registry-based study on survival and 
care of cancer patients) data5 concluded that the sur-
vival gap for both ovarian and cervical cancers could 
be reduced by improvements in early diagnosis.
Survival rates for both cancers vary by stage at diag-
nosis with better prognosis among women diagnosed 
with early-stage disease.6–8 Most cervical cancer deaths 
(80%) occur in women aged over 45 years and the 
majority of these deaths are among women who have 
not attended screening. Attending for screening, and 
(for young girls) receiving the human papillomavirus 
(HPV) vaccine, are the most effective ways to pre-
vent cervical cancer. However, if cancer does develop, 
early detection promotes better survival. Several early 
warning signs for cervical cancer have been identi-
fied, including bleeding between menstrual periods, 
after sex, or after the menopause, and pain during 
sex.9 Knowledge of these warning signs could improve 
women’s ability to identify the significance of symp-
toms and may encourage prompt help-seeking.
There is currently no available screening programme 
for ovarian cancer and only a fifth of ovarian cancers 
are diagnosed at an early stage in the UK.4 Contrary to 
previous thinking, recent evidence indicates that there 
are detectable warning signs and symptoms, which are 
included in the ovarian cancer ‘Key Messages’ pub-
lished by the Department of Health in 2009.10 A simi-
lar consensus statement on ovarian cancer symptoms 
was produced in the USA in 2007.11 Public awareness 
of these warning signs, alongside confidence to present 
at primary care, could reduce patient-attributable delay 
and ensure earlier stage at diagnosis.
Smoking and being overweight are potentially modi-
fiable risk factors for cervical and ovarian cancers, 
respectively. Raising awareness of these risk factors 
would be a step towards promoting behaviour change 
and risk reduction.12 Other risk factors are not amena-
ble to change (e.g. family history of breast or ovarian 
cancer as a risk factor for ovarian cancer, or having 
a weakened immune system for cervical cancer), but 
public awareness could facilitate appropriate personal 
risk perceptions and prompt help-seeking.
The aim of this study was to develop and validate 
comprehensive measures of ovarian and cervical can-
cer awareness that would be suitable for identifying 
gaps in public awareness, monitoring the impact of 
awareness-raising initiatives, and identifying popula-
tion subgroups that might benefit from targeted infor-
mation about these cancers.
Methods
Generation of items
The ovarian CAM and the cervical CAM follow the 
format of the generic CAM.2 Awareness of warning 
signs and risk factors is assessed first with an open-
ended question and then with a prompted checklist. 
The list includes all the established warning signs and 
risk factors, without any distracter items. We identified 
risk factors and warning signs for ovarian and cervical 
cancer using the scientific literature as well as cancer 
information materials and websites. In addition, the 
Department of Health’s ‘Key Messages’ on ovarian 
and cervical cancer were used to identify the accepted 
warning signs.9 10
Anticipated time to seeking help for a possible 
warning sign is assessed on a scale from ‘1–3 days’ to 
‘never’. Perceived lifetime risk of cancer is assessed 
in the generic CAM by asking how many people out 
of 100 will develop cancer at some point in their 
lives. Because the lifetime risk of cervical cancer is 
less than 1 per 100 women this item was adapted 
for the cervical CAM so that risk was estimated per 
1000 women.
Knowledge of the cancer screening programmes 
is measured in the generic CAM. The cervical CAM 
assessed awareness of the NHS cervical screening and 
HPV vaccination programmes and the age of invita-
tion for each. The ovarian CAM used questions from 
the generic CAM assessing knowledge of all three 
NHS cancer screening programmes and also asked 
participants whether there is an ovarian cancer screen-
ing programme.
The cervical and ovarian CAMs included an item on 
awareness of the peak age of incidence of each cancer 
(now part of the generic CAM) (see http://tinyurl.com/
CAMdownloads), and the cervical CAM asked about 
women’s confidence about noticing a cervical cancer 
symptom.
Expert review
First drafts of the ovarian and cervical CAMs were cir-
culated to a panel of experts (n=5 and 7, respectively), 
including academic researchers and clinical specialists, 
to ensure content validity. The panels were asked to 
comment on the content and comprehensiveness of the 
questionnaire as well as item terminology and word-
ing. A number of minor changes were made to the 
draft questionnaires following this review. The major-
ity of comments on the ovarian CAM related to the 
risk factor section. There was discussion of what the 
most relevant items were and the state of the current 
evidence. Specifically, the wording and items that were 
modified related to going through the menopause, a 
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diagnosis of endometriosis or ovarian cysts, and being 
childless. There was discussion about the inclusion of 
‘using talcum powder in the genital area’ as it was felt 
that this would not apply to many women. However, 
because the aim was to maintain a comprehensive list 
of risk factors, this item was retained because it has 
been widely publicised as a risk factor and the evidence 
has not yet ruled it out. However, future users of the 
ovarian CAM may wish to omit this item if more con-
clusive evidence becomes available.
In the cervical CAM, ‘infection with herpes’ was 
removed from the risk factor checklist as experts com-
mented that the evidence for this as a risk factor was 
inconclusive and ‘taking the contraceptive pill’ was 
changed to ‘long-term use of the contraceptive pill’. 
The item ‘not having regular baths or showers’ was 
removed because experts thought that it was a myth 
and ‘having a poor diet’ was removed as likely to be 
a marker of socioeconomic status. The experts also 
changed the warning sign ‘vaginal discharge’ to ‘per-
sistent vaginal discharge’.
Validating the ovarian and cervical CAMs
The psychometric properties of the measures were 
assessed in terms of internal reliability, test-retest reli-
ability, item analyses, construct validity and sensitivity 
to changes in levels of awareness. Parametric statistics 
(e.g. Pearson’s correlation, t-tests) were used to analyse 
reliability and validity. The open-ended warning sign 
and risk factor questions were not suitable for use in 
the reliability and test-retest analyses. However these 
questions were used in the analyses for construct valid-
ity (experts vs control) and sensitivity to change. Data 
were analysed using SPSS 18.0® (IBM SPSS, Amronk, 
NY, USA). 
The versions of the ovarian and cervical CAMs used 
in the validation process are summarised in Table 1. 
They consisted of 11 items on awareness of warning 
signs for the ovarian CAM and 12 items for the cervical 
CAM, 11 on anticipated time to seek medical advice in 
the ovarian CAM and one in the cervical CAM [NB. 
The ovarian CAM asked about anticipated delay for 
each symptom as well as a generic item, whereas the 
cervical CAM used only the generic item “If you had 
a symptom that you thought might be a sign of cervi-
cal cancer how soon would you contact your doctor to 
make an appointment to discuss it?”], 13 items on risk 
factors for ovarian cancer and 12 items on risk factors 
for cervical cancer, one item on age of peak ovarian/cer-
vical cancer incidence, eight items on awareness of NHS 
screening programmes in the ovarian CAM, and four 
items on the NHS cervical screening and vaccination 
programmes in the cervical CAM. The cervical CAM 
also included an item on confidence in detecting a cervi-
cal cancer symptom. The module on ‘barriers to seek-
ing medical advice’, already developed for the generic 
CAM, was included and can be used as an optional scale 
in the ovarian and cervical CAMs but is not included in 
the validation analyses (10 items). Both questionnaires 
can be requested at http://tinyurl.com/CAMdownloads.
Samples
Sample 1 (test-retest reliability)
Twenty-two women recruited from among relatives of 
university staff completed the ovarian CAM via a tel-
ephone interview. For the cervical CAM, 22 female 
postgraduate students were recruited from three non-
medical MSc courses. They completed a supervised 
paper and pencil version of the questionnaire and were 
monitored to ensure they did not refer back to previous 
answers. Both samples were selected from age-appropri-
ate groups, that is an older age group (45–67 years) for 
the ovarian CAM and younger age group (21–40 years) 
for the cervical CAM, to reflect the age-associated risk 
for each cancer. These samples completed the measure 
twice (7–10 days apart) to assess test-retest reliability.
Sample 2 (sensitivity to changes in knowledge)
This sample consisted of female postgraduate students 
and staff from the university finance department who 
Table 1  Summary of items in each section of the ovarian and cervical Cancer Awareness Measures (CAMs)
Awareness section Ovarian CAM Cervical CAM
Warning signs 1 open item 1 open item
10 prompted items 11 prompted items
Risk factors 1 open item 1 open item
12 prompted items 11 prompted items
Peak age of incidence 1 item 1 item
Awareness of screening/vaccination programmes 8 items (1 included in the scoring) 4 items
Anticipated time to help-seeking 11 items (one for each warning sign 
and one for a suspected ovarian cancer 
symptom)
1 item (for a suspected cervical cancer symptom)
Lifetime risk of ovarian/cervical cancer* 1 item 1 item
Conﬁ  dence in detecting a symptom – 1 item
Barriers to help-seeking (optional module from generic CAM) 10 items 10 items
*This item showed poor reliability and validity so is not included in the ﬁ  nal validated measures.
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Peak age of incidence
This item was scored as correct (score=1) if a partici-
pant answered that the age most likely to develop ovar-
ian cancer was either 70 years or 50 years, but incorrect 
(score=0) for the response ‘30 years old’. While the 
true answer could be considered to be 70 years, mes-
saging from ovarian cancer charities often focuses on 
women who are 50 years and older, so both responses 
were considered valid in this instance. For cervical can-
cer the item was scored correct (score=1) if the par-
ticipant answered ‘30–49 years old’.
Awareness of screening/vaccination programmes
In the ovarian CAM, participants were given a score 
of 1 if they knew that there is not an NHS screening 
programme for ovarian cancer. In the cervical CAM, 
participants were given a maximum score of 4 if they 
were aware of the cervical screening and vaccination 
programmes, and knew the ages at which these are 
offered (25 years was the correct response for screen-
ing and ages between 12–18 years were counted as 
correct for vaccination).
Lifetime risk
Answers to this item were recorded verbatim and recoded 
into correct (score=1) for responses of 1–2 out of 100 
for ovarian cancer and 6–10 out of 1000 for cervical 
cancer, and incorrect (score=0) for other responses.
Total knowledge
For the ovarian CAM, an overall knowledge score was 
calculated by adding together scores for the prompted 
warning signs and risk factors, peak age of incidence, 
lifetime risk and awareness that there is no NHS screen-
ing programme for ovarian cancer. [NB. The items 
on other NHS screening programmes are included to 
add context to the ovarian screening question but are 
not included in the scoring of the questionnaire. The 
questionnaire could be administered without these 
‘filler’ items.] This produced a scale where higher 
scores indicated greater knowledge about ovarian can-
cer (maximum score=73) [NB. The item on lifetime 
risk was subsequently dropped from the measure (see 
below) leaving a maximum score of 72.] For the cer-
vical CAM, the knowledge score was calculated from 
prompted warning signs and risk factors, age of peak 
incidence, lifetime risk and awareness of the cervical 
screening and vaccination programmes and the ages at 
which they are offered. Higher scores indicated greater 
knowledge (maximum score=72). [NB. The item on 
lifetime risk was subsequently dropped from the meas-
ure (see below) leaving a maximum score of 71.]
Results
Item analyses
Item discrimination shows whether individual items 
can discriminate between people with higher or lower 
knowledge. This test was applied for all items where it 
was possible to ascertain a correct answer. The items 
volunteered in response to publicity about the study. 
Fifty-two participants completed either face-to-face 
interviews or supervised paper and pencil versions 
of the ovarian CAM and 50 participants completed 
a supervised computer-based version of the cervical 
CAM. Participants from each group were randomised 
to read one of two leaflets before completing the 
CAM; either an educational leaflet on the cancer in 
question (‘Ovarian/Cervical Cancer: The Facts’) or a 
control leaflet (‘Recycle to Save the Environment’). 
There were 27 and 25 participants in the ovarian and 
cervical intervention groups, respectively, and 25 in 
each control group. These samples were recruited 
to test the questionnaire’s sensitivity to changes in 
awareness.
Sample 3 (ovarian/cervical cancer experts)
This sample comprised 13 experts on ovarian cancer 
and 19 experts on cervical cancer recruited using a 
‘snowballing’ method through cancer charities, known 
gynaecologists and those who had been involved in the 
development of the measures. Participants took part 
in telephone interviews for the ovarian CAM and an 
online version of the cervical CAM. The expert groups 
were compared with a control group who had equiva-
lent educational qualifications from Sample 2 using the 
‘known-groups’ method to establish construct validity. 
Differences in the scores of two groups known to dif-
fer in levels of cancer knowledge support the validity 
of the questionnaire.13
Item scoring
Warning signs and risk factors
The open questions can be explored in a number of 
ways depending on the interest of the researcher (e.g. 
correct vs incorrect responses). In these analyses, one 
point was given to each warning sign or risk factor 
that corresponded to an item in the prompted list. This 
method scores ‘correct’ items. Scores were added to 
give a total score with the range 0–10 (ovarian) and 
0–11 (cervical) for warning signs, and 0–12 (ovarian) 
and 0–11 (cervical) for risk factors. Higher scores indi-
cate greater knowledge.
The prompted warning signs items were scored as 
either 0 (no/don’t know) or 1 (yes). Scores from each 
item were summed to produce a total symptom knowl-
edge scale (range: 0–10 for ovarian and 0–11 for cervi-
cal), with higher scores indicating greater knowledge. 
The prompted risk factor items were scored from 1 
(strongly disagree) to 5 (strongly agree). A summed 
scale was produced with higher scores indicating 
greater knowledge (range: 12–60 for the ovarian CAM 
and 12–55 for the cervical CAM).
Anticipated time to help-seeking
The items on anticipated time to help-seeking for 
symptoms were scored individually on an ordinal scale 
from 1 (1–3 days) to 10 (never). Higher scores indicate 
greater delay in help-seeking.
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Reliability and validity
Test-retest reliability
To be sure that questionnaire responses are non-
  random and stable over time, test-retest reliability was 
calculated14 using Pearson’s correlations between the 
scores from two time-points. Sample 1 was used to 
assess test-retest reliability. High correlations (I>0.80) 
were found for the ovarian CAM as a whole, and for 
the sections on warning signs, time to seek medical 
advice, peak age of incidence of ovarian cancer and 
lifetime risk. Moderate correlations (I>0.55) were 
found for sections on risk factors and awareness that 
there is no ovarian screening programme (Table 2).
High correlations (r>0.80) were found for the cervi-
cal CAM as a whole, as well as sections on help-seeking, 
awareness of the cervical screening programme, and 
age invited for vaccination. Satisfactory correlations 
(r>0.70) were found for sections on warning signs, risk 
factors, peak age of incidence, age invited for screening 
and awareness of the vaccination programme. Moderate 
correlations were found for lifetime risk (r=0.58) and 
confidence noticing a symptom (r=0.55) (Table 2). 
Because of its poor reliability in this and other tests, the 
lifetime risk item was removed from the measure and 
was not included in the total awareness score for the 
cervical CAM for this or other analyses.
Sensitivity to change
Data from Sample 2 were used to test whether the 
measures were sufficiently sensitive to detect the likely 
modest increase in knowledge achieved by allowing 
participants to read an information leaflet on ovar-
ian/cervical cancer (compared with a leaflet on recy-
cling). There were no significant differences in age, 
educational level or ethnic origin between the groups 
randomised to intervention or control groups for the 
ovarian CAM. The results showed that after reading 
the leaflets, the intervention group scored higher than 
the control group on all the ovarian CAM sections 
(Table 3) except lifetime risk of cancer. As with the 
cervical CAM, the lifetime risk item was removed from 
the measure and was not included in the total aware-
ness score for this or subsequent analyses (Table 3).
Those in the cervical CAM intervention group scored 
significantly higher than the control group on all sec-
tions apart from peak age of incidence, awareness of 
the cervical screening programme and age invited for 
vaccination (Table 3) where, although more interven-
tion participants answered the questions correctly, the 
difference from the control group was non-significant. 
Demographic data showed that the intervention group 
had significantly higher educational qualifications than 
controls, but the significant between-group differences 
in knowledge persisted after controlling for education 
(analyses not shown).
Internal reliability
Internal reliability uses Cronbach’s α to assess the 
extent to which all the questionnaire items measure 
asking about confidence at detecting a cervical cancer 
symptom and help-seeking were not included as they are 
not measuring cancer knowledge per se. Items with an 
item-to-total correlation of >0.2 are considered useful.11 
Participants from Samples 1, 2 and 3 were combined in 
these analyses. Item-to-total correlations for the ovarian 
CAM were greater than 0.2 for the majority of items. The 
exception was the warning sign ‘pain in pelvis’ (r=0.19) 
but this item was retained to ensure content validity 
because it is part of the ovarian cancer ‘Key Messages’.10 
For the cervical CAM, all items had item-total correla-
tions >0.2 except the warning sign item ‘bleeding after 
the menopause’ (r=0.11). Again, this item was retained 
because to ensure content validity.
To assess item difficulty we analysed results from 
Sample 1 and the control group from Sample 2. This 
analysis allows exploration of item properties and it 
has been suggested that items answered correctly by 
20–80% of respondents should be retained.14 The 
majority of items in the ovarian CAM fell within this 
range. A few items received higher rates of correct 
answers (e.g. identifying pain in the pelvis as a warn-
ing sign). The majority of items in the cervical CAM 
were also answered correctly by between 20% and 
80% of respondents. A few items had fewer than 20% 
answering correctly (‘persistent diarrhoea’ as a warn-
ing sign; ‘long term use of the contraceptive pill’, ‘hav-
ing many children’ and ‘having a sexual partner who is 
not circumcised’ as risk factors). Additionally, several 
items were answered correctly by more than 80% of 
respondents but it was decided to retain all of these 
items on the basis of content validity.
Table 2  Test-retest reliability of the ovarian and 
cervical Cancer Awareness Measures (CAMs) 







Warning signs (prompted) 0.83 0.76
Risk factors (prompted) 0.60 0.77
Lifetime risk 0.96 0.58
Peak age of incidence 0.91 0.73
Ovarian screening programme 0.56 –
Anticipated time to help-seeking 0.88 0.92
Conﬁ  dence noticing a symptom – 0.55
Cervical screening programme – 1.00
Age when invited for screening – 0.80
Vaccination programme – 0.73
Age invited for vaccination – 0.81
Total knowledge score 0.84* 0.77†
*Total = Prompted warning signs + Prompted risk factors + Peak age of 
incidence + Ovarian screening programme + Lifetime risk.
†Total = Prompted warning signs + Prompted risk factors + Peak age 
of incidence + Cervical screening programme + Age women invited for 
screening + Vaccination programme + Age invited for vaccination.
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supported.13 Participants from Sample 2 (control group 
only) and Sample 3 (ovarian/cervical cancer experts) 
were used in these analyses. Ovarian and cervical can-
cer experts scored consistently higher than the group 
of university staff and students (Table 4). Differences 
between the groups were statistically significant in all 
sections of the ovarian CAM (p<0.001). Awareness of 
the age of peak incidence of cervical cancer, aware-
ness of the cervical screening programme and age of 
invitation for HPV vaccination did not differ signifi-
cantly between groups, but a higher percentage of 
experts answered these questions correctly compared 
to controls.
Discussion
The ovarian and cervical CAMs were developed to 
provide validated measures of awareness of ovarian 
and cervical cancer. Reliability of both measures was 
good, with Cronbach’s α of >0.8 and good test-retest 
reliability for most sections. The only item that per-
formed poorly across the validation studies was the 
lifetime risk question. Cervical cancer risk was greatly 
overestimated by both lay and expert groups, with 
only 21% of experts answering it correctly. It had poor 
the same underlying construct.14 A score of >0.7 is 
needed for a scale to be considered internally relia-
ble.15 Samples 1, 2 and 3 were combined for the analy-
sis, and items with a correct response were included 
(as with the item analyses described earlier). For the 
ovarian CAM, Cronbach’s α of 0.88 was achieved for 
the knowledge scale (without the lifetime risk item), 
with the following alphas obtained for each subsec-
tion: warning signs=0.77, anticipated time to help-
seeking=0.92 and risk factors=0.86.
For the cervical CAM, Cronbach’s α for the total 
knowledge measure (excluding the lifetime risk item) 
was 0.84, with the following alphas obtained for each 
subsection: warning signs=0.77 and risk factors=0.77. 
Other sections in the cervical and ovarian CAMs 
had too few items to be considered scales. Although 
responses to open questions can be coded correct or 
incorrect, this is not a true scale and therefore was not 
included in this analysis.
Construct validity: cancer experts vs control group
The ‘known-groups’ method was employed to establish 
construct validity. If the scores of two groups known 
to differ in levels of cancer awareness are significantly 
different then the validity of the questionnaire is 
Table 3  Differences in Cancer Awareness Measure (CAM) scores between control and intervention participants 
[t-tests and Chi-square (χ2) tests]
Ovarian CAM Cervical CAM
Control 
(n = 25) 
Mean (SD)
Intervention 







Mean (SD) Awareness section t (df) p t (df) p
Warning signs (open)
Max: 10 Ovarian/11 Cervical
 0.8 (0.7)   5.2 (4.8)   10.8 (49) <0.001  0.8 (1.2)  5.1 (2.6)   –7.4  (48) <0.001
Warning signs (prompted)
Max: 10 Ovarian/11 Cervical
 4.9 (1.6)   8.4 (2.4)  6.2 (50) <0.001  5.9 (2.6)  9.3 (2.4)   –4.8  (48) <0.001
Risk factors (open)
Max: 12 Ovarian/11 Cervical
 1.6 (1.5)   4.9 (1.6)  7.6 (49) <0.001  0.8 (0.9)  3.8 (2.1)   –6.4  (48) <0.001
Risk factors (prompted)
Max: 60 Ovarian/55 Cervical
37.6  (3.3)   45.9  (6.5)   5.7  (50) <0.001  35.7  (5.0)  43.2  (6.2)   –4.7  (48) <0.001
n (%) n (%) χ2 pn  (%) n (%) χ2 p
Peak age of incidence (correct)  14  (56)   26  (96)  11.9 0.001  11  (44)  17  (68)   2.9 0.09
Awareness of screening 
programme (correct)
  10 (42)   19 (70)   9.2 0.01   19 (76)   22 (88)   1.2 0.27
Age women invited for 
screening (correct)
– – – –  4  (16)   16  (64) 12.0 0.001
Awareness of vaccination 
programme (correct)
– – – –  14  (56)  21  (84) 4.7 0.03
Age invited for vaccination (correct) – – – –  15  (60)  19  (76) 1.5 0.23
Lifetime risk (correct)   3  (12)   8  (30)   2.4 0.12 – – – –
Mean (SD) Mean (SD) t (df) p Mean (SD) Mean (SD) t (df) p
Total knowledge score
Max: 73 Ovarian*/71 Cervical†
 44.1  (4.3)  56.8  (7.2)  7.5 (49)  <0.001  44.1  (6.8)  56.3  (8.6)  –5.5 (48) <0.001
* Total Ovarian CAM knowledge = Prompted warning signs + Prompted risk factors + Peak age of incidence + Ovarian screening programme.
†Total Cervical CAM knowledge = Prompted warning signs + Prompted risk factors + Peak age of incidence + Cervical screening programme + Age women 
invited for screening + Vaccination programme + Age invited for vaccination.
df, degrees of freedom; max, maximum; SD, standard deviation.
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scores than an equally-educated control group. This 
was reinforced by the results from the intervention 
studies, which showed that both measures were sensi-
tive to increases in awareness following a brief educa-
tional intervention.
There were some limitations to this study. The mode 
of administration varied across stages of piloting, and 
included face-to-face, telephone, computer-based and 
paper-and-pencil versions, although all were done 
under controlled conditions. The exception was the 
expert panel in the cervical CAM who completed an 
online version in non-controlled conditions, but it was 
designed so that participants could not return to previous 
answers. Experts were also reminded that they should 
not consult colleagues or search the Internet if they did 
not know the answer. In addition, the non-expert study 
participants were better educated than the population 
as a whole, which limits generalisation to other popula-
tions. Future users of the cervical CAM should also be 
aware of items that are answered correctly by a particu-
larly high or low proportion of respondents. At present, 
we recommend retaining these items because omitting 
well-known risk factors would compromise the face and 
content validity of the measure, and it is important to 
examine change in the lesser-known items.
test-retest reliability in the cervical CAM and showed 
poor sensitivity to change in the ovarian CAM. The 
item was removed from both measures.
In the ovarian CAM, awareness of screening pro-
grammes did not reach the conventional test-retest 
reliability threshold, but this was not due to major 
change between the two administrations, but a change 
from ‘no’ to ‘don’t know’ or vice versa. In fact, none 
of the participants responded ‘yes’ at either time point 
and therefore this result is relatively unimportant in 
terms of questionnaire consistency. It does indicate 
that most women are aware that no ovarian screening 
programme exists. Responses to the risk factor items 
also showed only moderate reliability, which may have 
been a learning effect between the two administra-
tions, because overall risk factor scores were higher in 
the second round. However, there was still a relatively 
high correlation, and it is likely that with a longer 
interval between administrations any learning effect 
would be diminished if there was not an additional sys-
tematic intervention to support it. Future intervention 
studies using the ovarian and cervical CAMs may wish 
to explore this further.
Construct validity was established: people with 
expertise in ovarian/cervical cancer achieved higher 
Table 4  Differences in Cancer Awareness Measure (CAM) scores between control and expert participants [t-tests 
and Chi-square (χ2) tests]
Ovarian CAM Cervical CAM
Control 
(n = 25) 
Mean (SD)
Expert 
(n = 13) 
Mean (SD)
Control 
(n = 25) 
Mean (SD)
Expert 
(n = 19) 
Mean (SD) Awareness section t (df) p t (df) p
Warning signs (open)
Max: 10 Ovarian/11 Cervical
  0.8 (0.7)   6.5  (2.6)   –10.3 (36) <0.001   0.8 (1.2)   3.6 (1.2)  –7.9 (42) <0.001
Warning signs (prompted)
Max: 10 Ovarian/11 Cervical)
  4.9 (1.6)   8.8  (1.9)   –6.9 (36) <0.001   5.8 (2.6)   8.5 (1.7)  –3.8 (42) <0.001
Risk factors (open)
Max: 12 Ovarian/11 Cervical
 1.6  (1.5)  4.5 (1.8)  –5.13  (36) <0.001   0.8  (0.9)   3.0  (1.6)   –5.7  (42 <0.001
Risk factors (prompted)
Max: 60 Ovarian/55 Cervical
 37.6 (3.3)  42.1  (4.8)   –3.3 (36) 0.002   35.7 (5.0)  40.0 (6.3)  –2.5 (40) 0.02
n (%) n (%) χ2 pn  (%) n (%) χ2 p
Peak age of incidence (correct)  14  (56)   13  (100) 8.1 0.005   11  (44)   12  (67)   2.2 0.14
Awareness of screening 
programme (correct)
 10  (42)  13  (100) 12.2 0.002   19  (76)   16  (94)   2.4 0.12
Age women invited for 
screening (correct)
– – – –  4  (16)   15  (94)   23.7 <0.001
Awareness of vaccination 
programme (correct)
– – – –  14  (56)  15  (94)  6.7 0.01
Age invited for 
vaccination (correct)
– – – –  15  (60)  13  (81)  2.0 0.15
Mean (SD) Mean (SD) t (36) p Mean (SD) Mean (SD) t (df) p
Total knowledge score
Max: 72 Ovarian*/71 Cervical†
 44.1 (4.3)  53.9  (6.3)  –5.6  (35) <0.001  44.1 (6.8)  52.7 (7.5)  –3.7 (38) 0.001
*Total Ovarian CAMowledge = Prompted warning signs + Prompted risk factors + Peak age of incidence + ovarian screening programme.
†Total Ovarian CAMowledge = Prompted warning signs + Prompted risk factors + Peak age of incidence + Cervical screening programme + Age women 
invited for screening + Vaccination programme + Age invited for vaccination.
df, degrees of freedom; max, maximum; SD, standard deviation.
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Testing of both the ovarian and cervical CAMs was 
thorough in terms of the types and variety of reliability 
and validity studies carried out, but further testing in 
community samples will also be needed to demonstrate 
utility. Finally, since the development of the ovarian 
CAM, the National Institute for Health and Clinical 
Excellence has published draft clinical guidelines for 
the recognition and initial management of ovarian can-
cer.16 These state that clinicians should “consider carry-
ing out tests in primary care if a woman reports having 
abnormal vaginal bleeding” (page 39). Abnormal vagi-
nal bleeding was not included as a warning sign in the 
ovarian CAM because item choice was driven primarily 
by the Department of Health’s ‘Key Messages’ which, 
at the time of development, did not include this symp-
tom. However recent evidence has demonstrated that 
abnormal vaginal bleeding, particularly postmenopau-
sal bleeding, has positive predictive value in relation 
to ovarian as well as endometrial cancer.17 Therefore 
future users of the ovarian CAM may wish to consider 
inclusion of the ‘bleeding after the menopause’ item as 
used in the cervical CAM. Future users may also wish 
to add an item measuring confidence in detecting an 
ovarian cancer symptom which, although not part of 
the original generic CAM, has been validated in sev-
eral of the site-specific versions, including the cervical 
CAM, and has now been included in the generic CAM 
too (readers are referred to the cervical CAM for the 
wording of this item).
The ovarian and cervical CAMs are reliable and 
valid measures of awareness of risk factors and early 
symptoms of these two cancers. Further tests using 
community samples are required, but these results 
indicate that they could be useful tools to provide 
a comprehensive assessment of ovarian and cervi-
cal cancer awareness or to assess the effectiveness of 
interventions designed to target gaps in awareness of 
these cancers either in whole populations or specific 
subgroups.
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